DeCure for Neurodevelopmental disorder with speech impairment and dysmorphic facies
DeCure's autonomous Psychiatry AI scientist is researching a drug-repurposing hypothesis for neurodevelopmental disorder with speech impairment and dysmorphic facies — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleNeurodevelopmental disorder with speech impairment and dysmorphic facies maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for neurodevelopmental disorder with speech impairment and dysmorphic facies is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
SET domain containing 1A, histone lysine methyltransferase (SETD1A) — SETD1A is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet unxdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3S8S · 1.3 Å · ligand UNKNOWN ATOM OR ION (UNX). Experimental structure, not a prediction.
What the evidence adds up to
CNOT3 variants cause an autosomal dominant neurodevelopmental disorder with speech delay, autism, and dysmorphic facies. Two families now show parent-child transmission, overturning the earlier assumption that all cases were de novo. The phenotype varies substantially even within the same family. No drug or intervention is mentioned in this abstract.
Specific language impairment (SLI) is heritable and linked to at least fifteen genes, including FOXP2, ATP2C2, CMIP, CNTNAP2, and GRIN2A. The 2021 review lists common non-synonymous variants for each gene and discusses their possible pathophysiological impact, but it does not report any clinical trial or drug treatment.
Shprintzen-Goldberg syndrome, caused by SKI exon 1 variants, includes developmental delay, intellectual disability (borderline to moderate in all four patients studied), and emotional/behavioural dysregulation. In a combined cohort of 56 individuals, 80% (45/56) had developmental or cognitive impairment; the remainder had normal intelligence. Mean age was 23 years. Again, no drug is tested or proposed.
Across these abstracts, no drug is investigated, no treatment is given, and no repurposing candidate is identified. What is missing is any clinical trial, any pharmacological intervention, any patient stratification strategy, and any funding for such work. The genetic causes are increasingly clear, but the path from gene discovery to therapy remains unopened.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Clinical Genetics · 2020 · 25 citations · open access
Inherited cases of <scp><i>CNOT3</i></scp>‐associated intellectual developmental disorder with speech delay, autism, and dysmorphic facies
AbstractDe novo pathogenic variants in CNOT3 have recently been reported in a developmental delay disorder (intellectual developmental disorder with speech delay, autism, and dysmorphic facies [IDDSADF, OMIM: #618672]). The patients present with a variable degree of developmental delay and behavioral problems. To date, all reported disease-causing variants occurred de novo and no parent-child transmission was observed. We report for the first time autosomal dominant transmissions of the CNOT3-associated developmental disorder in two unrelated families. The clinical characteristics in our patients match the IDDSADF features reported so far and suggest substantial variability of the phenotype within the same family.
Suez Canal University Medical Journal · 2021 · 2 citations · open access
Specific Language Impairment Genes, Variants and Possible Gene-based Interventions
AbstractSpecific Language Impairment (SLI) is a communication neurodevelopmental disorder that manifests at the age of 3-5 years when a child lags his chronological speech development age by one year in the absence of medical, environmental, and psychological risk factors. SLI has been known to be highly heritable. Many studies have demonstrated different genes and loci to be implicated in SLI through linkage studies, the commonest of which were, FOXP2, ATP2C2, CMIP, CNTNAP2, DCDC2, KIAA0319, DYX1C1, SRPX2, NFXL1, ERC1, SETBP1, SEMA6D, AUTS2, and GRIN2A and B. In this review, we aim to present a comprehensive summary of the genes reported to be responsible or correlated to SLI and the common non-synonymous variants for each gene and their potential pathophysiological impact on normal speech development.
America's Children and the Environment: Neurodevelopmental Disorders (Excerpt from the Third Edition)
AbstractNeurodevelopmental disorders are disabilities associated primarily with the functioning of the neurological system and brain. Examples of neurodevelopmental disorders in children include attention-deficit/hyperactivity disorder (ADHD), autism, learning disabilities, intellectual disability (also known as mental retardation), conduct disorders, cerebral palsy, and impairments in vision and hearing. Children with neurodevelopmental disorders can experience difficulties with language and speech, motor skills, behavior, memory, learning, or other neurological functions. While the symptoms and behaviors of neurodevelopmental disabilities often change or evolve as a child grows older, some disabilities are permanent. Diagnosis and treatment of these disorders can be difficult; treatment often involves a combination of professional therapy, pharmaceuticals, and home-and school-based programs.
Clinical Genetics · 2024 · 1 citations · open access
Exploring the Cognitive and Behavioral Aspects of Shprintzen‐Goldberg Syndrome; a Novel Cohort and Literature Review
AbstractShprintzen-Goldberg-syndrome (SGS) is caused by pathogenic exon 1 variants of SKI. Symptoms include dysmorphic features, skeletal and cardiovascular comorbidities, and cognitive and developmental impairments. We delineated the neurodevelopmental and behavioral features of SGS, as they are not well-documented. We collected physician-reported data of people with molecularly confirmed SGS through an international collaboration. We identified and deep-phenotyped the neurodevelopmental and behavioral features in four patients. Within our cohort, all exhibited developmental delays in motor skills and/or speech, with the average age of first words at 2 years and 6 months and independent walking at 3 years and 5 months. All four had learning disabilities and difficulties regulating emotions and behavior. Intellectual disability, ranging from borderline to moderate, was present in all four participants. Moreover, we reviewed the literature and identified 52 additional people with SGS, and summarized the features across both datasets. Mean age was 23 years (9-48 years). When combining our cohort and reported cases, we found that 80% (45/56) had developmental and/or cognitive impairment, with the remainder having normal intelligence. Our study elucidates the developmental, cognitive, and behavioral features in participants with SGS and contributes to a better understanding of this rare condition.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
